Abstract
Thirty-seven eligible patients with advanced non-Hodgkin's lymphoma of low-grade, T-cell intermediate- and high-grade histology were treated with pentostatin (2′-deoxycoformycin, dCF) 4 mg2 i.v. weekly for 3 weeks and then every 14 days to be followed after 3 doses by the same dosage every 4 weeks until maximum response or progression. Only patients with no more than two chemotherapy regimens were entered in this trial. All patients had measurable disease, performance status of 1,0 and 2 and adequate bone marrow, renal and liver function. Five of 37 eligible patients experienced a partial response of 8 months' median duration (range 7-12). The response rate was 17% in low-grade, 8% in T-cell intermediate- and high-grade and 14% in cutaneous T cell lymphoma. The only eligible patient with Hodgkin's disease underwent progression while on treatment. One case presented with grade 3 leukopenia and another one died of septicaemia, possibly treatment-related. Elevated but reversible creatinine levels were observed in 13% of patients and conjunctivitis in 7%. The toxicity of dCF at this low-dose schedule was acceptable, but the therapeutic activity in pretreated patients with low-grade, T-cell intermediate- and high-grade and cutaneous T-cell lymphomas was limited.
| Original language | English |
|---|---|
| Pages (from-to) | 163-168 |
| Number of pages | 6 |
| Journal | Oncology |
| Volume | 53 |
| Issue number | 2 |
| Publication status | Published - Mar 1996 |
Fingerprint
Keywords
- Malignant lymphomas
- Pentostatin
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Pentostatin (2′-deoxycof ormycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas : Phase II study of the EORTC early clinical trials group. / Monfardini, S.; Sorio, R.; Cavalli, F.; Cerny, T. H.; Van Glabbeke, M.; Kaye, S.; Smyth, J. F.
In: Oncology, Vol. 53, No. 2, 03.1996, p. 163-168.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pentostatin (2′-deoxycof ormycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas
T2 - Phase II study of the EORTC early clinical trials group
AU - Monfardini, S.
AU - Sorio, R.
AU - Cavalli, F.
AU - Cerny, T. H.
AU - Van Glabbeke, M.
AU - Kaye, S.
AU - Smyth, J. F.
PY - 1996/3
Y1 - 1996/3
N2 - Thirty-seven eligible patients with advanced non-Hodgkin's lymphoma of low-grade, T-cell intermediate- and high-grade histology were treated with pentostatin (2′-deoxycoformycin, dCF) 4 mg2 i.v. weekly for 3 weeks and then every 14 days to be followed after 3 doses by the same dosage every 4 weeks until maximum response or progression. Only patients with no more than two chemotherapy regimens were entered in this trial. All patients had measurable disease, performance status of 1,0 and 2 and adequate bone marrow, renal and liver function. Five of 37 eligible patients experienced a partial response of 8 months' median duration (range 7-12). The response rate was 17% in low-grade, 8% in T-cell intermediate- and high-grade and 14% in cutaneous T cell lymphoma. The only eligible patient with Hodgkin's disease underwent progression while on treatment. One case presented with grade 3 leukopenia and another one died of septicaemia, possibly treatment-related. Elevated but reversible creatinine levels were observed in 13% of patients and conjunctivitis in 7%. The toxicity of dCF at this low-dose schedule was acceptable, but the therapeutic activity in pretreated patients with low-grade, T-cell intermediate- and high-grade and cutaneous T-cell lymphomas was limited.
AB - Thirty-seven eligible patients with advanced non-Hodgkin's lymphoma of low-grade, T-cell intermediate- and high-grade histology were treated with pentostatin (2′-deoxycoformycin, dCF) 4 mg2 i.v. weekly for 3 weeks and then every 14 days to be followed after 3 doses by the same dosage every 4 weeks until maximum response or progression. Only patients with no more than two chemotherapy regimens were entered in this trial. All patients had measurable disease, performance status of 1,0 and 2 and adequate bone marrow, renal and liver function. Five of 37 eligible patients experienced a partial response of 8 months' median duration (range 7-12). The response rate was 17% in low-grade, 8% in T-cell intermediate- and high-grade and 14% in cutaneous T cell lymphoma. The only eligible patient with Hodgkin's disease underwent progression while on treatment. One case presented with grade 3 leukopenia and another one died of septicaemia, possibly treatment-related. Elevated but reversible creatinine levels were observed in 13% of patients and conjunctivitis in 7%. The toxicity of dCF at this low-dose schedule was acceptable, but the therapeutic activity in pretreated patients with low-grade, T-cell intermediate- and high-grade and cutaneous T-cell lymphomas was limited.
KW - Malignant lymphomas
KW - Pentostatin
UR - http://www.scopus.com/inward/record.url?scp=0029869521&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029869521&partnerID=8YFLogxK
M3 - Article
C2 - 8604244
AN - SCOPUS:0029869521
VL - 53
SP - 163
EP - 168
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - 2
ER -